Any current/future capex/capital investment/strategic investment?

For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth. The significant portion of capex will be directed towards the Gajraula Multi-purpose Plant (MPP), expected to commence production in Q4 FY27. The company has recently capitalized its CDMO plant in March, leading to a reduction in capital work-in-progress. Continued investments align with the Pinnacle growth journey and are aimed at fueling expansion in Fine Chemicals, CDMO, Nutrition, and Specialty segments. Strategic acquisition includes Remidex Pharma to strengthen the Human Nutrition pr

Any current/future new fundraising through debt or equity?

No explicit mention of any current or future fundraising through debt or equity in the transcript provided. The company continues to invest through capex in the range of Rs. 400-500 crore yearly for growth (Page 10). Capital work-in-progress has reduced due to plant capitalization, indicating ongoing internal funding of projects (Page 10). The management highlights confidence in organic growth and profitability without mentioning the need for external fundraising (Page 15). Net debt-to-EBITDA ratio stands at 0.99, indicating manageable leverage (Page 6). Overall, the company seems focused on i

Future growth expectations in sales/revenue/volumes?

The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. Specialty Chemicals and Nutrition segments are projected to lead growth, supported by volume recovery and price stability. CDMO business is poised for nonlinear growth, targeting 3x to 4x scaling over the Pinnacle Journey, driven by multiple innovative molecules in agro, pharma, and personal care. The large agro contract and other multi-year contracts provide visibility for steady or improved volumes, though some customer volume finalizations remain pending due to m

Future growth expectations in earnings/operating earnings/profits/EPS?

Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27. Sequential growth in revenue and EBITDA is expected starting from Q1 FY27. Growth drivers include Specialty Chemicals, Nutrition, and recovery in acetyls segments. The large $300 million agro CDMO contract, started in March FY27, is a key pillar for growth projections. The company anticipates a ramp-up in CDMO opportunities across agro, pharma, semiconductors, and personal care, contributing to incremental revenue over 3 years. Sustainable EBITDA margin guidance for Specialty Chemicals is maintained a

Current/ Expected Orderbook/ Pending Orders?

Jubilant Ingrevia currently has over 100 CDMO opportunities with a potential of approximately Rs. 3,500 crore. There are 20+ confirmed molecules and an additional pipeline of 10+ advanced stage molecules with a peak potential of Rs. 1,100 crore. The company secured a significant $300 million CDMO contract started shipping in March FY26, which forms a major pillar for growth in the current year. The overall CDMO order book is around Rs. 1,500 crore with various projects at different stages of development. New molecules are added every quarter; recent additions include 8 new molecules on top of

IN US

Sale is live|00:00:00left today

Jubilant Ingrevia LtdQ1 FY26Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹632P/E: 42.4Market Cap: ₹11.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward.
→Specialty Chemicals and Nutrition segments are projected to lead growth, supported by volume recovery and price stability.
→CDMO business is poised for nonlinear growth, targeting 3x to 4x scaling over the Pinnacle Journey, driven by multiple innovative molecules in agro, pharma, and personal care.
→The large agro contract and other multi-year contracts provide visibility for steady or improved volumes, though some customer volume finalizations remain pending due to market volatility.
→Pipeline of 100+ opportunities with Rs. 3,500 crore potential in CDMO, including phased growth (20-25% peak revenue in Year 1, 50-60% in Year 2, 80%+ in Year 3).
→Nutrition business, notably Human Nutrition premixes, expected to grow rapidly post recent acquisition.
→European market share gains anticipated due to competitor force majeure and plant disruptions.
→Sustained Specialty Chemicals EBITDA margins targeted at 23-25%.

Margin guidance

Category 3

→Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27.
→Sequential growth in revenue and EBITDA is expected starting from Q1 FY27.
→Growth drivers include Specialty Chemicals, Nutrition, and recovery in acetyls segments.
→The large $300 million agro CDMO contract, started in March FY27, is a key pillar for growth projections.
→The company anticipates a ramp-up in CDMO opportunities across agro, pharma, semiconductors, and personal care, contributing to incremental revenue over 3 years.
→Sustainable EBITDA margin guidance for Specialty Chemicals is maintained at 23%-25%, adjusted for corporate overhead.
→Management confident of meeting Pinnacle Journey's target of 3x revenue and 4x EBITDA growth by FY30.
→Opportunities from acquisitions (e.g., Remidex Pharma) and new geographies (Japan, Southeast Asia) support growth.
→Pricing volatility and market disruptions are being managed, with potential positive impacts from European capacity constraints.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or future fundraising through debt or equity in the transcript provided.
→The company continues to invest through capex in the range of Rs. 400-500 crore yearly for growth (Page 10).
→Capital work-in-progress has reduced due to plant capitalization, indicating ongoing internal funding of projects (Page 10).
→The management highlights confidence in organic growth and profitability without mentioning the need for external fundraising (Page 15).
→Net debt-to-EBITDA ratio stands at 0.99, indicating manageable leverage (Page 6).
→Overall, the company seems focused on internal cash flows, operational efficiencies, and organic growth rather than seeking new debt or equity at this time.

Order book

Yes

→Jubilant Ingrevia currently has over 100 CDMO opportunities with a potential of approximately Rs. 3,500 crore.
→There are 20+ confirmed molecules and an additional pipeline of 10+ advanced stage molecules with a peak potential of Rs. 1,100 crore.
→The company secured a significant $300 million CDMO contract started shipping in March FY26, which forms a major pillar for growth in the current year.
→The overall CDMO order book is around Rs. 1,500 crore with various projects at different stages of development.
→New molecules are added every quarter; recent additions include 8 new molecules on top of 15 announced previously.
→Growth expectation: New projects typically begin contributing 20-25% of peak revenue in year 1, 50-60% in year 2, and 80%+ in year 3.
→Discussions and progress continue with global agrochemical and pharma majors, expanding the CDMO portfolio.

Capex plans

Yes

→For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth.
→The significant portion of capex will be directed towards the Gajraula Multi-purpose Plant (MPP), expected to commence production in Q4 FY27.
→The company has recently capitalized its CDMO plant in March, leading to a reduction in capital work-in-progress.
→Continued investments align with the Pinnacle growth journey and are aimed at fueling expansion in Fine Chemicals, CDMO, Nutrition, and Specialty segments.
→Strategic acquisition includes Remidex Pharma to strengthen the Human Nutrition premixes portfolio, aiding forward integration.
→The capex investment supports scaling up operations, new molecule launches, and capacity enhancements to meet growing demand across pharma, agro, personal care, and semiconductor sectors.

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Jubilant Ingrevia Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Jubilant Ingrevia Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio